Reconstruction of the regulatory hypermethylation network controlling hepatocellular carcinoma development during hepatitis C viral infection
Author:
Antropova Evgeniya A.1ORCID, Khlebodarova Tamara M.12, Demenkov Pavel S.123ORCID, Volianskaia Anastasiia R.3, Venzel Artur S.12ORCID, Ivanisenko Nikita V.12ORCID, Gavrilenko Alexandr D.13, Ivanisenko Timofey V.12ORCID, Adamovskaya Anna V.23, Revva Polina M.23, Kolchanov Nikolay A.13ORCID, Lavrik Inna N.4ORCID, Ivanisenko Vladimir A.123ORCID
Affiliation:
1. Institute of Cytology and Genetics, Siberian Branch of RAS , Novosibirsk , Russia 2. Kurchatov Genomic Center of the Institute of Cytology and Genetics of Siberian Branch of the Russian Academy of Sciences , Novosibirsk , Russia 3. Novosibirsk State University , Novosibirsk , Russia 4. Translational Inflammation Research, Medical Faculty , Otto von Guericke University Magdeburg , 39106 Magdeburg , Germany
Abstract
Abstract
Hepatocellular carcinoma (HCC) has been associated with hepatitis C viral (HCV) infection as a potential risk factor. Nonetheless, the precise genetic regulatory mechanisms triggered by the virus, leading to virus-induced hepatocarcinogenesis, remain unclear. We hypothesized that HCV proteins might modulate the activity of aberrantly methylated HCC genes through regulatory pathways. Virus-host regulatory pathways, interactions between proteins, gene expression, transport, and stability regulation, were reconstructed using the ANDSystem. Gene expression regulation was statistically significant. Gene network analysis identified four out of 70 HCC marker genes whose expression regulation by viral proteins may be associated with HCC: DNA-binding protein inhibitor ID – 1 (ID1), flap endonuclease 1 (FEN1), cyclin-dependent kinase inhibitor 2A (CDKN2A), and telomerase reverse transcriptase (TERT). It suggested the following viral protein effects in HCV/human protein heterocomplexes: HCV NS3(p70) protein activates human STAT3 and NOTC1; NS2-3(p23), NS5B(p68), NS1(E2), and core(p21) activate SETD2; NS5A inhibits SMYD3; and NS3 inhibits CCN2. Interestingly, NS3 and E1(gp32) activate c-Jun when it positively regulates CDKN2A and inhibit it when it represses TERT. The discovered regulatory mechanisms might be key areas of focus for creating medications and preventative therapies to decrease the likelihood of HCC development during HCV infection.
Funder
Ministry of Science and Higher Education of the Russian Federation within the ERA-NET Target identification and drug development in liver cancer
Publisher
Walter de Gruyter GmbH
Reference68 articles.
1. Ahmad, FB, Cisewski, JA, Anderson, RN. Provisional mortality data – United States, 2021. MMWR Morb Mortal Wkly Rep 2022;71:597–600. https://doi.org/10.15585/mmwr.mm7117e1. 2. Yang, JD, Hainaut, P, Gores, GJ, Amadou, A, Plymoth, A, Roberts, LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol 2019;16:589–604. https://doi.org/10.1038/s41575-019-0186-y. 3. Goodgame, B, Shaheen, NJ, Galanko, J, El-Serag, HB. The risk of end stage liver disease and hepatocellular carcinoma among persons infected with hepatitis C virus: publication bias? Am J Gastroenterol 2003;98:2535–42. https://doi.org/10.1111/j.1572-0241.2003.07678.x. 4. Fasani, P, Sangiovanni, A, De Fazio, C, Borzio, M, Bruno, S, Ronchi, G, et al.. High prevalence of multinodular hepatocellular carcinoma in patients with cirrhosis attributable to multiple risk factors. Hepatology 1999;29:1704–7. https://doi.org/10.1002/hep.510290604. 5. Stroffolini, T, Andreone, P, Andriulli, A, Ascione, A, Craxì, A, Chiaramonte, M, et al.. Gross pathologic types of hepatocellular carcinoma in Italy. Oncology 1999;56:189–92. https://doi.org/10.1159/000011963.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|